Publication | Closed Access
Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity.
205
Citations
33
References
1986
Year
Immunocytochemical TechniqueImmunologyImmunodominanceAntigen ProcessingImmunotherapeuticsImmunotherapyAntibody EngineeringRadiation OncologyEffector T-cell ActivityAutoimmunityT Cell ImmunityAntibody ScreeningBispecific Monoclonal AntibodyParental Hybridoma LinesCell BiologyTumor MicroenvironmentBispecific Hybrid AntibodyMonoclonal AntibodiesMedicineHybrid Hybridoma
Previous studies have shown that heteroconjugates of monoclonal antibodies in which one of the component antibodies is directed at the T-cell receptor and the other is directed against any chosen site can focus effector T cells to function at the targeted site. We report here the production of a hybrid hybridoma cell line, H1.10.1.6, which secretes large amounts of a bispecific hybrid antibody of the IgG2a class, that can focus T-cell activity. The parental hybridoma lines for the secondary fusion were F23.1, which secretes an antibody specific for an allotypic determinant on the T-cell receptor of most mouse strains, and 19E12, secreting an anti-Thy-1.1 antibody. The bispecific hybrid antibody was partially purified by hydroxylapatite chromatography and characterized by isoelectric focusing. It efficiently targets Thy-1.1-expressing tumor cells for lysis by F23.1 receptor-positive cytotoxic T-cell clones in vitro. Such hybrid antibodies produced by hybrid hybridoma cell lines may have application in the therapeutic targeting of tumors or sites of viral infections for attack by T cells.
| Year | Citations | |
|---|---|---|
Page 1
Page 1